SUBSCRIBE
SUBSCRIBE

Foresee Pharmaceuticals

IN THE PRESS
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing
June 27, 2023
 · 
2 min read
Foresee Pharmaceuticals Presented Poster on MMP-12 Inhbitor, FP-020, in Genetic Model of Sarcoidosis at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs)
June 21, 2023
 · 
4 min read
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs)
June 16, 2023
 · 
2 min read
Business
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development
April 17, 2023
 · 
3 min read
Business
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
February 23, 2022
 · 
3 min read
FDA
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord BioPharma to Head the U.S. Commercialization
May 26, 2021
 · 
4 min read
Drug Development
Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS
March 27, 2021
 · 
3 min read
Deals
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
December 24, 2020
 · 
2 min read
Business
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi(TM) in China
November 17, 2020
 · 
4 min read
Foresee Pharmaceuticals Announces NDA for CAMCEVI(TM) 42MG Accepted for Review by the FDA
October 8, 2020
 · 
2 min read
Load More
JOBS